NXL

Nexalin Technology, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Owens DavidDirector, Officer: Chief Medical Officer
$1.3k2k shares
BuyJun 10, 2024
$0.65
--
Owens DavidDirector, Officer: Chief Medical Officer
$6201k shares
BuyJun 10, 2024
$0.62
--
Owens DavidDirector, Officer: Chief Medical Officer
$1.1k1.6k shares
BuyJun 18, 2024
$0.71
--
Owens DavidDirector, Officer: Chief Medical Officer
$1.8k1k shares
BuyJun 28, 2024
$1.75
--
Owens DavidDirector, Officer: Chief Medical Officer
$9501k shares
BuyAug 13, 2024
$0.95
--
Owens DavidDirector, Officer: Chief Medical Officer
$1.1k500 shares
BuyOct 28, 2024
$2.19
--

News

globenewswire.comNexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Lifeglobenewswire.comJun 16globenewswire.comNexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.globenewswire.comJun 10globenewswire.comNexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomniaglobenewswire.comJun 4globenewswire.comNexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injuryglobenewswire.comMay 21globenewswire.comNexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trialglobenewswire.comMay 19